Dr. Katherine Matthay is the chief of Pediatric Hematology-Oncology at UCSF Benioff Children's Hospital and has been focused for more than 20 years on translational research in neuroblastoma, a deadly childhood cancer. At UCSF, she has developed and led multiple trials using a unique targeted radiopharmaceutical, 131I-MIBG for neuroblastoma.
Dr. Matthay also leads the UCSF Pediatric Malignancies Program and an NIH funded Phase I New Approaches to Neuroblastoma Therapy consortium (NANT) for treatment of relapsed and resistant neuroblastoma.
I am a pediatric oncologist and physician-scientist with a focus on examining new therapeutic strategies for sarcomas. Whether using genetic and biochemical tools for discovery, preclinical models for target and biomarker validation, or participating in the care of patients on clinical trials, my goal is to align my research and clinical practice to improve cure rates and quality of life for these patients.